A Polypill for Secondary Prevention of Ischemic Heart Disease
Status:
Recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
Cardiovascular diseases (CVD) are the leading cause of mortality and morbidity worldwide. The
most important aspect of CVD secondary prevention is adherence to guideline-indicated
pharmacological therapy which globally remains low. In previous studies, a Polypill
containing fixed dose combination of essential drugs have improved patient adherence to these
drugs. The effect of such a strategy on pharmacological therapy uptake, cost-effectiveness,
and CVD recurrence in our setting will be assessed in this study. Participants hospitalized
in three referral hospitals in Isfahan, Iran because of an acute myocardial infarction (MI)
(ST elevation MI (STEMI) or non-ST elevation MI (NSTEMI)) will be randomized to either
receiving Polypill or usual care after MI. Patient recruitment will be carried out at the
time of patient discharge from the hospitals.